StreetAccount Summary - US Pre-market trading update
GENFIT reports H1 net income (€10.0M) vs year-ago €30.3M - 6-K (€3.29, 0.00)
StreetAccount Summary - Trading higher/lower: EU mid-morning
StreetAccount Summary - European pre-market trading update
GENFIT to discontinue VS-01 program in ACLF (€3.61, 0.00)
HC Wainwright assumes GNFT, VALN
StreetAccount Sector Summary - Healthcare Post-Market
FDA grants orphan drug designation to elafibranor for primary sclerosing cholangitis (PSC) (€105.70, 0.00)
Powered by FactSet Research Systems Inc.